The Pharmacy Times® Neurology resource center provides clinical news and articles, information about upcoming conferences and meetings, updated clinical trial listings, and other resources.
What can we help you find?
A final vote that assessed whether the findings from the EMERGE trial served as primary evidence for the efficacy of aducanumab in Alzheimer disease was 10–0 that the trial did not provide evidence.
The current acute treatments for migraines have shown efficacy and safety, however, approximately one-third of people do not respond, cannot use these options due to contraindications, or report dissatisfaction in therapy.
Simple sugar found in breast milk and dietary supplements may promote myelin repair in patients with multiple sclerosis.
Approximately half of the people with multiple sclerosis (MS) have the HLA-DR15 gene variant, which is responsible for up to 60% of genetic risk.
Research has also shown that patients with Parkinson disease who are able to engage in physical activity can potentially improve the motor and non-motor symptoms associated with the disease.
Ubrogepant (Ubrelvy, Allergan) was approved for the treatment of acute migraines with or without aura in adults after showing a significantly greater reduction in headache pain compared with placebo.
VX-765, a novel multiple sclerosis drug, works by inhibiting a component of inflammasomes that promotes harmful inflammation.
Several risk factors for multiple sclerosis, such as disease progression and fatigue, increase the risk of unemployment.
Women who had longer reproductive periods during their lifetimes were found to have a greater risk of dementia in older age compared with those who had shorter reproductive periods.
Dimethyl fumarate is indicated to treat relapsing forms of multiple sclerosis in adult patients.
Integrating specialty pharmacy staff into oncology, neurology, rheumatology, and other specialty clinics within their health systems is a growing trend with a range of beneficial outcomes.
Individuals with asymptomatic Alzheimer disease are more likely to fall than those who are not on track to develop dementia.